BodyTom 64 (NL4100); OmniTom Elite (NL5000)
Samsung HME America, Inc., dba NeuroLogica Corp. · Decision date Sep 22, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on September 22, 2026 for K261125, a traditional 510(k) submitted by Samsung HME America, Inc., dba NeuroLogica Corp. of Danvers, Massachusetts, covering the BodyTom 64 (NL4100) and OmniTom Elite (NL5000) computed tomography x-ray systems under 21 CFR 892.1750, Class II, product code JAK, in the radiology specialty. The submission was received April 6, 2026, and the review was not performed by a third party.
The cleared change is software only: the Samsung Weighted Filtered Back Projection (S-FBP) reconstruction algorithm, identical for both systems, with no hardware changes. The summary names BodyTom 64 (K242811) as predicate and OmniTom Elite (K233767) as reference device, and states the indications for use are unchanged and identical to those of the predicates. The summary reports a statistically significant reduction in image noise with S-FBP; independent clinical performance data are not in the provided record.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Sep 22, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261125
- Regulatory pathway
- 510(k) premarket notification
- Product code
- JAK
- Decision code
- SESE
- Decision date
- Sep 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, X-Ray, Tomography, Computed.
- Product code
- JAK
- FDA device class
- 2
FDA decision timeline
K261125 received
Application receipt date recorded by FDA.
K261125 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code JAK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AVIEW Aorta MetricsK260391 | Coreline Soft Co., Ltd. | 510(k) clearance | Oct 16, 2026 | FDA |
CAS-One IRK261225 | Cascination AG | 510(k) clearance | Sep 29, 2026 | FDA |
SCENARIA View Phase 6.0K261229 | Fujifilm Corporation | 510(k) clearance | Sep 18, 2026 | FDA |
FCT iStream Phase 2K253836 | Fujifilm Corporation | 510(k) clearance | Sep 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Samsung HME America, Inc., dba NeuroLogica Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Danvers, MA
Sources and methodology
- Original FDA record: K261125
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


